These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 30791698

  • 1. Treatment Recommendations for Tardive Dyskinesia.
    Ricciardi L, Pringsheim T, Barnes TRE, Martino D, Gardner D, Remington G, Addington D, Morgante F, Poole N, Carson A, Edwards M.
    Can J Psychiatry; 2019 Jun; 64(6):388-399. PubMed ID: 30791698
    [Abstract] [Full Text] [Related]

  • 2. Selecting Treatment for Patients With Tardive Dyskinesia Using Safety and Efficacy Evidence.
    McEvoy JP.
    J Clin Psychiatry; 2020 Sep 29; 81(6):. PubMed ID: 32991793
    [Abstract] [Full Text] [Related]

  • 3. Treatment of tardive dyskinesia with VMAT-2 inhibitors: a systematic review and meta-analysis of randomized controlled trials.
    Solmi M, Pigato G, Kane JM, Correll CU.
    Drug Des Devel Ther; 2018 Sep 29; 12():1215-1238. PubMed ID: 29795977
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Deuterium Tetrabenazine for Tardive Dyskinesia.
    Cummings MA, Proctor GJ, Stahl SM.
    Clin Schizophr Relat Psychoses; 2018 Jan 29; 11(4):214-220. PubMed ID: 29341821
    [Abstract] [Full Text] [Related]

  • 9. VMAT2 Inhibitors for Tardive Dyskinesia-Practice Implications.
    Peckham AM, Nicewonder JA.
    J Pharm Pract; 2019 Aug 29; 32(4):450-457. PubMed ID: 29455579
    [Abstract] [Full Text] [Related]

  • 10. Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.
    Caroff SN, Aggarwal S, Yonan C.
    J Comp Eff Res; 2018 Feb 29; 7(2):135-148. PubMed ID: 28965423
    [Abstract] [Full Text] [Related]

  • 11. Valbenazine for the treatment of tardive dyskinesia.
    Müller T.
    Expert Rev Neurother; 2017 Dec 29; 17(12):1135-1144. PubMed ID: 28971695
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FDA-Approved Medications to Treat Tardive Dyskinesia.
    McEvoy JP.
    J Clin Psychiatry; 2019 Dec 17; 81(1):. PubMed ID: 31851437
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Valbenazine in the treatment of tardive dyskinesia.
    Witek N, Comella C.
    Neurodegener Dis Manag; 2019 Apr 17; 9(2):73-81. PubMed ID: 30724115
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder.
    McIntyre RS, Calabrese JR, Nierenberg AA, Farahmand K, Yonan C, Siegert S, Burke J.
    J Affect Disord; 2019 Mar 01; 246():217-223. PubMed ID: 30583148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.